Prophylactic TLR9 stimulation reduces brain metastasis through microglia activation

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Metastasis

Background:

• Brain metastases are a frequent and fatal complication of various cancers.
• Current therapies for brain metastases have limited efficacy, highlighting the need for preventative strategies.

Purpose of the Study:

• To investigate the efficacy of systemic prophylactic administration of a toll-like receptor (TLR) 9 agonist, CpG-C, against brain metastases.
• To elucidate the underlying mechanisms of CpG-C's anti-metastatic effects in the brain.

Main Methods:

• Systemic administration of CpG-C in mouse models of lung cancer and melanoma brain metastasis.
• Analysis of immune cell involvement (NK cells, monocytes) and glial cell (microglia, astrocytes) activation.
• In vitro and in vivo studies using imaging, gene expression analysis, and pharmacological inhibition.

Main Results:

• Systemic CpG-C administration reduced tumor cell seeding and growth in the brain across multiple models.
• CpG-C was taken up by brain cells (endothelial cells, astrocytes, microglia) without compromising blood-brain barrier integrity.
• Microglia, but not astrocytes, were identified as key mediators of CpG-C's anti-tumor effects through direct tumor cell killing and phagocytosis.

Conclusions:

• Prophylactic systemic administration of CpG-C is a promising strategy to prevent brain metastases.
• The anti-metastatic effect of CpG-C in the brain is primarily mediated by the activation of microglia.
• CpG-C treatment represents a novel therapeutic avenue targeting microglia-mediated anti-tumor immunity in the brain.